Use of Platelet Count and Serum Albumin to Predict Prognosis for an Elderly Adult with Diffuse Large B-Cell Lymphoma (DLBCL, Platelet-Albumin Score of Ochi et al)

Description

Ochi et al used the platelet count and serum albumin to predict outcome for an elderly patient with diffuse large B-cell lymphoma (DLBCL). The authors are from Kobe City Medical Center General Hospital, Kyoto Univeristy and the Institute of Biomedical Research and Innovation in Japan.

Patient selection: DLBCL, with age > 60 years of age

Exclusions: primary mediastinal, primary effusion, indolent, HIV-related

Therapy: rituximab and chemotherapy

Parameters, presumably at presentation and prior to therapy:

(1) platelet count per microliter

(2) serum albumin in g/dL

Platelet Count	Serum Albumin	Risk Group
>= 100,000 per µL	>= 3.5 g/dL	low
< 100,000 per µL	>= 3.5 g/dL	intermediate
>= 100,000 per µL	< 3.5 g/dL	intermediate
< 100,000 per µL	< 3.5 g/dL	high

The P-A score is the number of abnormal findings, and ranges from 0 to 2.

Risk Group	5-Year Overall Survival
Low	82%
intermediate	49%
High	20%

To read more or access our algorithms and calculators, please log in or register.

Use of Platelet Count and Serum Albumin to Predict Prognosis for an Elderly Adult with Diffuse Large B-Cell Lymphoma (DLBCL, Platelet-Albumin Score of Ochi et al)

Description

Specialty